Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ENGLEWOOD, Colo., Sept. 15, 2021 /PRNewswire/ --  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced top-line results from AP-013, a randomized, saline-controlled, double-blind Phase III clinical study evaluating the efficacy of an intra-articular (IA) injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee (OAK).

Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of Ampion in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK)

ENGLEWOOD, Colo., Aug. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced a preprint version of a manuscript, "LMWF5A Demonstrates an Anti-Inflammatory Mode of Action and Similar Drug Targets to Dexamethasone in Activated PBMC," has been posted on In Review, a preprint platform hosted on Research Square.

Ampio Pharmaceuticals Announces Important New Research Manuscript on Anti-Inflammatory Mode of Action

ENGLEWOOD, Colo., Aug. 12, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, reminds stockholders to vote on the proposals listed in the Company's proxy statement in advance of its upcoming annual meeting.

Ampio Pharmaceuticals Reminds Stockholders to Vote Shares in Advance of 2021 Annual Meeting

ENGLEWOOD, Colo., Aug. 11, 2021 /PRNewswire/ --  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that the company will host one-on-one investor meetings at the following investor conferences: H.C.

Ampio Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

Cinedigm

China Rapid Finance

Why penny stocks investors are showing bullish interest in these 3 small-caps The post Why Penny Stocks Investors Are Bullish on These 3 Small-Caps appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why Penny Stocks Investors Are Bullish on These 3 Small-Caps

A positive second-quarter earnings report and anticipation of further details to be discussed this afternoon helped this beaten-down biotech stock recover some previous losses.

Here's Why Ampio Pharmaceuticals Stock Is Surging Today

Ampio Pharmaceuticals, Inc. (AMPE) CEO Mike Macaluso on Q2 2021 Results - Earnings Call Transcript

ENGLEWOOD, Colo., Aug. 4, 2021 /PRNewswire/ --  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today reported results for the second quarter period ended June 30, 2021, and provided a corporate overview and business update.

Ampio Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update

ENGLEWOOD, Colo., July 29, 2021  /PRNewswire/ -- Ampio Pharmaceuticals  (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the Company's poster presentation, "Efficient Applied Toxicology during COVID-19: A Preclinical Study that Advanced Clinical Use of Ampion," being given virtually at the American College of Toxicology 42nd Annual Meeting, November 14 to 17, 2021, at the Gaylord National Harbor in Washington, DC.

Ampio Pharmaceuticals to Present at the American College of Toxicology 42nd Annual Meeting

ENGLEWOOD, Colo., July 28, 2021 /PRNewswire/ --  Ampio Pharmaceuticals  (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the Company's abstract presentation, "Significant Inhibition of the TLR7/CXCL10 Signaling Axis by LMWF5A in Monocytic Lineages; Implications for COVID-19 and Lupus Nephritis," being given virtually at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA) on October 6-9, 2021.

Ampio Pharmaceuticals to Present at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA)

ENGLEWOOD, Colo., July 27, 2021 /PRNewswire/ --  Ampio Pharmaceuticals  (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the Company's poster presentation, "Inflammation and COVID Induced ARDS: Inhaled Ampion™ as a Therapeutic Option," being given at the 63rd annual Thomas L.

Ampio Pharmaceuticals to Present at Aspen Lung Conference

ENGLEWOOD, Colo., July 14, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended June 30, 2021, and provide a corporate business update on Wednesday, August 4, 2021, at 4:30 pm EDT/ 2:30 pm MT.

Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Business Update

Acasti Pharma

Adamis Pharmaceuticals

BIOLASE

Jaguar Health

Northwest Biotherapeutics, Inc.

Are these the best biotech penny stocks to watch right now? The post Best Biotech Penny Stocks In Summer 2021?

Best Biotech Penny Stocks In Summer 2021? 7 For Your Watchlist

Ampio Pharmaceuticals, Inc. (NYSE: AMPE) announced an update to its COVID-19 program that is evaluating its lead asset Ampion. What Happened: Colorado-based Ampio announced the commencement of randomization and dosing of patients in the Phase 2 study, dubbed AP-019, of inhaled Ampion for the treatment of respiratory distress due to COVID-19.

Ampio's Phase 2 Study Of Inhaled Ampion In COVID-19 Patients Gets Underway

ENGLEWOOD, Colo., June 25, 2021 /PRNewswire/ --  Ampio Pharmaceuticals  (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced randomization and dosing of patients in its multi-center AP-019 Phase II clinical trial, using inhaled Ampion™ in the treatment of respiratory distress due to COVID-19, is underway.

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

ENGLEWOOD, Colo., June 18, 2021 /PRNewswire/ – Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that the Company is expected to join the small cap  Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of this year's reconstitution of the Russell stock indexes, effective after the U.S. stock market opens on Monday, June 28, 2021, accordingly to a preliminary list of additions posted on June 4, 2021.

Ampio Pharmaceuticals, Inc. to Join the Russell 2000® Index and Russell 3000® Index

ENGLEWOOD, Colo., June 17, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today reported newly integrated data from four of its earlier clinical trials with consistent inclusion, exclusion, and demographic populations utilizing Ampion for treating osteoarthritis of the knee (OAK).

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAK

Camber Energy

McEwen Mining

Best penny stocks to watch with vaccine rates higher than ever The post Hot Penny Stocks to Buy? 3 to Watch As Vaccine Rates Hit New Highs appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Buy? 3 to Watch As Vaccine Rates Hit New Highs

ENGLEWOOD, Colo., June 15, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it has received regulatory approval to expand enrollment of its AP-019 Phase II study to India.

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

ENGLEWOOD, Colo., June 14, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the Company's poster presentation, "Pivoting From One to Multiple Production Platforms to Treat COVID," being given at the 2021 International Society for Pharmaceutical Engineers (ISPE) Annual Meeting and Expo in Boston, Massachusetts from November 1 st to 3rd, 2021.

Ampio Pharmaceuticals to Present at the 2021 International Society for Pharmaceutical Engineers Annual Meeting and Expo

ENGLEWOOD, Colo., June 11, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that management will participate in a series of one-on-one meetings with institutional investors throughout the day at the Alliance Global Partners' Virtual Summer Healthcare Symposium on June 17, 2021.

Ampio Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Summer Healthcare Symposium

Ampio has existed for over a decade, and run more than a dozen trials for lead asset Ampion. Regulatory path is still unclear for osteoarthritis of the knee.

Ampio Pharmaceuticals: Regulatory Process Taking Too Long

ENGLEWOOD, Colo., May 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the company's poster presentation, "Regulatory Decisions during COVID-19: Efficient Nonclinical Inhalation Toxicology for a Clinical Program," being given at the 23rd International Congress of the International Society for Aerosols in Medicine (ISAM), in Boise, Idaho, May 22 to 26, 2021.

Ampio Pharmaceuticals to Present Poster at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress

ENGLEWOOD, Colo., May 10, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that it has received Investigational Review Board (IRB) approval to commence enrollment in its AP-018 Phase I study using inhaled Ampion™ with patients exhibiting prolonged respiratory COVID-19 symptoms, known as long (or long-haul) COVID, or Post-Acute Sequelae of SARS-CoV-2.

Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)

Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE), a biopharma developing immunology-based therapies for inflammatory diseases, announced Monday it has received approval to initiate a clinical study of its lead asset for long COVID-19 treatment. Ampion's COVID-19 Study: Englewood, Colorado-based Ampio said an investigational review board has approved the initiation of a Phase 1 study, dubbed AP-018, of its inhaled Ampion in patients exhibiting prolonged respiratory COVID-19 symptoms.

News for Ampio Pharmaceuticals Inc Stock (AMPE)